Ann Clin Microbiol 2025;28(4):26. Drug susceptibility testing for Mycobacterium tuberculosis: a narrative review
| Group | Anti-TB drug |
|---|---|
| A | Levofloxacin or Moxifloxacin Bedaquiline Delamanid Linezolid |
| B | Cycloserine Clofazimine |
| C | Amikacin or Kanamycin (Streptomycin) Ethambutol Imipenem-cilastatin or Meropenem Para-aminosalicylc acid (PAS) Prothionamide Pyrazinamide |
Group A: Highly effective core medicines that should be included in all longer MDR/RR-TB regimens unless contraindicated due to toxicity, intolerance, or known resistance; Group B: Companion medicines selected after Group A agents when constructing long regimens; Group C: Additional medicines that may be incorporated when an adequate regimen cannot be composed of Group A or B agents alone.
Abbreviation: TB, tuberculosis; MDR/RR-TB, multidrug-resistant/rifampicin-resistant TB.